ClinicalTrials.gg

Program

SR750 tablet

Its studies are mostly in Trigeminal Neuralgia, led by Shanghai SIMR Biotechnology.

Furthest: phase 2, since Aug 22, 20244 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Shanghai SIMR Biotechnology40 open or runningphase 2since Aug 22, 2024Sep 27, 2021none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 27, 2021First study: phase 1 study in Healthy VolunteersFirst studyNCT05083468 · 83 enrolled · Australia
  2. Feb 20, 2023Phase 1 study in HealthyNCT05753033 · 56 enrolled · China
  3. Aug 22, 2024Phase 2 study in Trigeminal NeuralgiaNCT06571448 · 138 enrolled · China
  4. Apr 10, 2025Phase 1 study in HealthyNCT06932536 · 40 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06932536Healthy · China1CompletedJul 7, 202540
NCT06571448Trigeminal Neuralgia · China2CompletedJan 26, 2026138
NCT05753033Healthy · China1CompletedSep 6, 202356
NCT05083468Healthy Volunteers · Australia1CompletedOct 14, 202283

How it is read

Names in the registry

  • “SR750 tablet”, 5 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.